PatentVest Pulse Report Highlights $10.7B FGF21 Deals Beyond GLP-1
MDBH•PatentVest Pulse’s new report analyzes over $10.7 billion in acquisitions and licensing by Novo Nordisk, Roche and GSK as FGF21 emerges as the next cardiometabolic layer beyond GLP-1. The report maps shifting intellectual property strategies and competitive platforms that could reshape MDBH’s PatentVest consulting and IP advisory offerings.
1. PatentVest Pulse Report Release
MDB Capital Holdings’ IP strategy arm, PatentVest, published a new PatentVest Pulse report titled "The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1." The report explores emerging FGF21 therapeutics and details how cardiometabolic drug development is shifting beyond first-generation GLP-1 therapies.
2. Strategic Acquisitions and Licensing Landscape
PatentVest analyzed more than $10.7 billion in acquisitions and licensing transactions by leading pharmaceutical companies including Novo Nordisk, Roche and GSK. The analysis highlights major strategic investments in FGF21 assets and partnership structures signaling industry confidence in FGF21’s potential.
3. FGF21’s Role Beyond GLP-1
The report examines FGF21’s complementary mechanism to GLP-1, addressing liver disease, lipid metabolism and chronic inflammation unresolved by GLP-1 treatments. Clinical programs and combination therapy approaches are mapped to illustrate how FGF21 could enhance obesity and cardiometabolic outcomes.
4. Intellectual Property Implications
An in-depth intellectual property landscape section outlines evolving patent strategies for combination platforms and FGF21 technologies. It assesses how emerging IP portfolios and prosecutorial approaches may shape long-term competitive positioning across the broader obesity therapeutics market.
